Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314664 · ClinicalTrials.gov registry record
A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- 15
- Enrollment target
NCT01314664: Clinical Trial study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT01314664 is a clinical trial that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01314664 was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01314664
The ClinicalTrials.gov registry entry for NCT01314664 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01314664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01314664 about?
NCT01314664 is a clinical study titled "A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)". The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.
What is the current status of trial NCT01314664?
This trial is currently terminated. The enrollment target is 15 participants. The study started on 2011-05. Estimated completion is 2012-01.
Who is sponsoring clinical trial NCT01314664?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.